In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis' NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIO-TTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.
Additional information
The online version of the original article can be found at 10.1038/nm0317-266
Rights and permissions
About this article
Cite this article
Correction. Nat Med 23, 404 (2017). https://doi.org/10.1038/nm0417-404
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0417-404
